May 23, 2017 07:30 AM EDTUpdated 07:43 AM

Bioverativ beefs up its pipeline of rare blood disease drugs with $825M True North buyout

John Carroll

Editor & Founder

Biogen spin-off Bioverativ isn’t just passively managing the portfolio of hemophilia drugs it’s been given. The biotech just struck a deal to buy South …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bioverativ beefs up its pipeline of rare blood disease drugs with $825M True North buyout

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Ionis’ treatment for a rare metabolic disorder

Sofinnova outlines $550M fund after IPOs and M&A deals

Biover­a­tiv beefs up its pipeline of rare blood dis­ease drugs with $825M True North buy­out

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Bioverativ beefs up its pipeline of rare blood disease drugs with $825M True North buyout

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Ionis’ treatment for a rare metabolic disorder

Sofinnova outlines $550M fund after IPOs and M&A deals